Recapitulating the α-helix: Nonpeptidic, low-molecular-weight ligands for the modulation of helix-mediated protein-protein interactions

Future Medicinal Chemistry

Volumn 5, Issue 18, 2013, Pages 2157-2174

  Lanning, Maryanna ^a   Fletcher, Steven ^a,b  

^a UNIVERSITY OF MARYLAND SCHOOL OF PHARMACY   (United States)

^b UNIVERSITY OF MARYLAND GREENEBAUM CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1,4 DIPIPERAZINOBENZENE; 3 HYDROXYBENZOIC ACID; 4 [4 (4' CHLORO 2 BIPHENYLYLMETHYL) 1 PIPERAZINYL] N [4 [3 DIMETHYLAMINO 1 (PHENYLTHIOMETHYL)PROPYLAMINO] 3 NITROBENZENESULFONYL]BENZAMIDE; 4 NITROBENZOIC ACID; AMIDE; AMYLIN; BENZODIAZEPINE; BENZOYLUREA DERIVATIVE; BIPHENYL AMINO ESTER; ENAMINONE DERIVATIVE; IMIDAZOLE; IMIDAZOLE DERIVATIVE; MOLECULAR SCAFFOLD; OLIGOOXOPIPERAZINE DERIVATIVE; PACLITAXEL; PEPTIDOMIMETIC AGENT; PICOLINAMIDE; PIPERAZINE DERIVATIVE; PROTEIN BAK; PROTEIN BCL X; PYRIDAZINE DERIVATIVE; PYRIDINE; PYRIDYLPYRIDONE; PYRROLOPYRIMIDINE DERIVATIVE; TEROXAZOLE DERIVATIVE; TERPHENYL DERIVATIVE; THIAZOLE; THIOAMIDE; TRIAZOLE DERIVATIVE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ALPHA HELIX; ANTINEOPLASTIC ACTIVITY; BIOLOGICAL PHENOMENA AND FUNCTIONS CONCERNING THE ENTIRE ORGANISM; CHEMICAL STRUCTURE; CRYSTAL STRUCTURE; DRUG DEVELOPMENT; HUMAN; HYDROGEN BOND; HYDROPHOBICITY; MODULATION; MOLECULAR MODEL; MOLECULAR RECOGNITION; MUTAGENESIS; NONHUMAN; NUCLEAR MAGNETIC RESONANCE; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; PROTEIN SECONDARY STRUCTURE; REVIEW; STRUCTURE ACTIVITY RELATION; X RAY CRYSTALLOGRAPHY;

LIGANDS; MOLECULAR MIMICRY; MOLECULAR WEIGHT; PROTEIN BINDING; PROTEINS;

EID: 84889572919     PISSN: 17568919     EISSN: 17568927     Source Type: Journal    
DOI: 10.4155/fmc.13.176     Document Type: Review

References (78)

1. Fletcher S, Hamilton AD. Protein surface recognition and proteomimetics: mimics of protein surface structure and function. Curr. Opin. Chem. Biol. 9(6), 632-638 (2005). (Pubitemid 41612192)
2. Smith MC, Gestwicki JE. Features of protein-protein interactions that translate into potent inhibitors: topology, surface area and affinity. Expert Rev. Mol. Med. 14, e16 (2012).
3. Nibbe RK, Chowdhury SA, Koyuturk M, Ewing R, Chance MR. Protein-protein interaction networks and subnetworks in the biology of disease. Wiley Interdiscip. Rev. Syst. Biol. Med. 3(3), 357-367 (2011).
4. Youle RJ, Strasser A. The BCL-2 protein family: opposing activities that mediate cell death. Nat. Rev. Mol. Cell Biol. 9(1), 47-59 (2008).
5. Mori M, Manetti F, Botta M. Targeting protein-protein and protein-nucleic acid interactions for anti-HIV therapy. Curr. Pharm. Des. 17(33), 3713-3728 (2011).
6. Al-Quobaili F, Montenarh M. Pancreatic duodenal homeobox factor-1 and diabetes mellitus type 2 (review). Int. J. Mol. Med. 21(4), 399-404 (2008). (Pubitemid 351802633)
7. Knight JD, Miranker AD. Phospholipid catalysis of diabetic amyloid assembly. J. Mol. Biol. 341(5), 1175-1187 (2004). (Pubitemid 39099208)
8. Lee LC, Maurice DH, Baillie GS. Targeting protein-protein interactions within the cyclic AMP signaling system as a therapeutic strategy for cardiovascular disease. Future Med. Chem. 5(4), 451-464 (2013).
9. Blazer LL, Neubig RR. Small molecule protein-protein interaction inhibitors as CNS therapeutic agents: current progress and future hurdles. Neuropsychopharmacology 34(1), 126-141 (2009).
10. Yin H, Hamilton AD. Strategies for targeting protein-protein interactions with synthetic agents. Angew. Chem. Int. Ed. 44, 4130-4163 (2005). (Pubitemid 40982718)
11. Clackson T, Wells JA. A hot spot of binding energy in a hormone-receptor interface. Science 267(5196), 383-386 (1995).
12. Bogan AA, Thorn KS. Anatomy of hot spots in protein interfaces. J. Mol. Biol. 280(1), 1-9 (1998). (Pubitemid 28312802)
13. Adams JM, Cory S. The Bcl-2 protein family: arbiters of cell survival. Science 281(5381), 1322-1326 (1998). (Pubitemid 28406819)
14. Boggetto N, Reboud-Ravaux M. Dimerization inhibitors of HIV-1 protease. Biol. Chem. 383(9), 1321-1324 (2002). (Pubitemid 35282949)
15. Schneider JP, Kelly JW. Templates that induce a-helical, b-sheet, and loop conformations. Chem. Rev. 95(6), 2169-2187 (1995).
16. Bouvier M, Taylor JW. Probing the Functional conformation of neuropeptide-Y through the design and study of cyclic analogs. J. Med. Chem. 35(6), 1145-1155 (1992).
17. Jackson DY, King DS, Chmielewski J, Singh S, Schultz PG. General approach to the synthesis of short a-helical peptides. J. Am. Chem. Soc. 113, 9391-9391 (1991).
18. Marqusee S, Baldwin RL. Helix stabilization by Glu-Lys+ salt bridges in short peptides of de novo design. Proc. Natl Acad. Sci. USA 84(24), 8898-8902 (1987).
19. Schafmeister CE, Po J, Verdine GL. An all-hydrocarbon cross-linking system for enhancing the helicity and metabolic stability of peptides. J. Am. Chem. Soc. 122(24), 5891-5892 (2000). (Pubitemid 30432299)
20. Davis JM, Tsou LK, Hamilton AD. Synthetic non-peptide mimetics of a-helices. Chem. Soc. Rev. 36(2), 326-334 (2007).
21. Cummings CG, Hamilton AD. Disrupting protein-protein interactions with non-peptidic, small molecule a-helix mimetics. Curr. Opin. Chem. Biol.14(3), 341-346 (2010).
22. Azzarito V, Long K, Murphy NS, Wilson AJ. Inhibition of a-helix-mediated protein- protein interactions using designed molecules. Nat. Chem. 5(3), 161-173 (2013).
23. Orner BP, Ernst JT, Hamilton AD. Toward proteomimetics: terphenyl derivatives as structural and functional mimics of extended regions of an a-helix. J. Am. Chem. Soc. 123(22), 5382-5383 (2001). (Pubitemid 32910693)
24. Kutzki O, Park HS, Ernst JT, Orner BP, Yin H, Hamilton AD. Development of a potent Bcl-x(L) antagonist based on a-helix mimicry. J. Am. Chem. Soc. 124(40), 11838-11839 (2002).
25. Kazi A, Sun J, Doi K et al. The BH3 a-helical mimic BH3-M6 disrupts Bcl-X(L), Bcl-2, and MCL-1 protein-protein interactions with Bax, Bak, Bad, or Bim and induces apoptosis in a Bax-and Bim-dependent manner. J. Biol. Chem. 286(11), 9382-9392 (2011).
26. Zhang HC, Nimmer P, Rosenberg SH, Ng SC, Joseph M. Development of a high-throughput fluorescence polarization assay for Bcl-x(L). Anal. Biochem. 307(1), 70-75 (2002).
27. Che Y, Brooks BR, Marshall GR. Protein recognition motifs: design of peptidomimetics of helix surfaces. Biopolymers 86(4), 288-297 (2007). (Pubitemid 47067546)
28. Ernst JT, Becerril J, Park HS, Yin H, Hamilton AD. Design and application of an a-helix-mimetic scaffold based on an oligoamide-foldamer strategy: antagonism of the Bak BH3/Bcl-xL complex. Angew. Chem. Int. Ed. 42, 535-539 (2003). (Pubitemid 36232248)
29. Saraogi I, Incarvito CD, Hamilton AD. Controlling curvature in a family of oligoamide a-helix mimetics. Angew. Chem. Int. Ed. 47, 9691-9694 (2008).
30. Saraogi I, Hebda JA, Becerril J, Estroff LA, Miranker AD, Hamilton AD. Synthetic a-helix mimetics as agonists and antagonists of islet amyloid polypeptide aggregation. Angew. Chem. Int. Ed. 49, 736-739 (2010).
31. Hebda JA, Saraogi I, Magzoub M, Hamilton AD, Miranker AD. A peptidomimetic approach to targeting pre-amyloidogenic states in Type II diabetes. Chem. Biol. 16(9), 943-950 (2009).
32. Ernst JT, Kutzki O, DebNath AK, Jiang S, Lu H, Hamilton AD. Design of a protein surface antagonist based on a-helix mimicry: inhibition of gp41 assembly and viral fusion. Angew. Chem. Int. Ed. Engl. 41(2), 278-281 (2002). (Pubitemid 34118069)
33. Plante J, Campbell F, Malkova B, Kilner C, Warriner SL, Wilson AJ. Synthesis of functionalised aromatic oligamide rods. Org. Biomol. Chem. 6(1), 138-146 (2008). (Pubitemid 350255968)
34. Ahn JM, Han SY. Facile synthesis of benzamides to mimic an a-helix. Tetrahedron Lett. 48, 3543-3547 (2007).
35. Prabhakaran P, Azzarito V, Jacobs T et al. Conformational properties of O-alkylated benzamides. Tetrahedron 68, 4485-4491 (2012).
36. Yap JL, Cao XB, Vanommeslaeghe K et al. Relaxation of the rigid backbone of an oligoamide-foldamer-based a-helix mimetic: identification of potent Bcl-x(L) inhibitors. Org. Biomol. Chem. 10(15), 2928-2933 (2012).
37. Dudkina AS, Lindsley CW. Small molecule protein-protein inhibitors for the p53-MDM2 interaction. Curr. Top. Med. Chem. 7(10), 952-960 (2007). (Pubitemid 47040522)
38. Plante JP, Burnley T, Malkova B et al. Oligobenzamide proteomimetic inhibitors of the p53-hDM2 protein-protein interaction. Chem. Commun. (Camb.) 34, 5091-5093 (2009).
39. Vassilev LT, Vu BT, Graves B et al. In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science 303(5659), 844-848 (2004). (Pubitemid 38174664)
40. Azzarito V, Prabhakaran P, Bartlett AI et al. 2-O-Alkylated para-benzamide a-helix mimetics: the role of scaffold curvature. Org. Biomol. Chem. 10(32), 6469-6472 (2012).
41. Lee TK, Ahn JM. Solid-phase synthesis of tris-benzamides as a-helix mimetics. ACS Comb. Sci. 13(2), 107-111 (2011).
42. Long K, Edwards TA, Wilson AJ. Microwave assisted solid phase synthesis of highly functionalized N-alkylated oligobenzamide a-helix mimetics. Bioorg. Med. Chem. 21(14), 4034-4040 (2013).
43. Cao X, Yap JL, Newell-Rogers MK et al. The novel BH3 a-helix mimetic JY-1-106 induces apoptosis in a subset of cancer cells (lung cancer, colon cancer and mesothelioma) by disrupting Bcl-xL and Mcl-1 protein-protein interactions with Bak. Mol. Cancer 12(1), 42 (2013).
44. Lee EF, Czabotar PE, Smith BJ et al. Crystal structure of ABT-737 complexed with Bcl-xL: implications for selectivity of antagonists of the Bcl-2 family. Cell. Death Differ. 14(9), 1711-1713 (2007). (Pubitemid 47278856)
45. Whitby LR, Boger DL. Comprehensive peptidomimetic libraries targeting protein-protein interactions. Acc. Chem. Res. 45(10), 1698-1709 (2012).
46. Yin H, Lee GI, Sedey KA et al. Terephthalamide derivatives as mimetics of helical peptides: disruption of the Bcl-x(L)/Bak interaction. J. Am. Chem. Soc. 127(15), 5463-5468 (2005). (Pubitemid 40569857)
47. Shaginian A, Whitby LR, Hong S et al. Design, synthesis, and evaluation of an a-helix mimetic library targeting protein-protein interactions. J. Am. Chem. Soc. 131(15), 5564-5572 (2009).
48. Whitby LR, Boyle KE, Cai L, Yu X, Gochin M, Boger DL. Discovery of HIV fusion inhibitors targeting gp41 using a comprehensive a-helix mimetic library. Bioorg. Med. Chem. Lett. 22(8), 2861-2865 (2012).
49. Chan DC, Chutkowski CT, Kim PS. Evidence that a prominent cavity in the coiled coil of HIV type 1 gp41 is an attractive drug target. Proc. Natl Acad. Sci. USA 95(26), 15613-15617 (1998). (Pubitemid 29018748)
50. Parks DJ, Lafrance LV, Calvo RR et al. Enhanced pharmacokinetic properties of 1,4-benzodiazepine-2,5-dione antagonists of the HDM2-p53 protein-protein interaction through structure-based drug design. Bioorg. Med. Chem. Lett. 16(12), 3310-3314 (2006). (Pubitemid 44304453)
51. Cummings MD, Schubert C, Parks DJ et al. Substituted 1,4-benzodiazepine- 2,5-diones as a-helix mimetic antagonists of the HDM2-p53 protein-protein interaction. Chem. Biol. Drug Des. 67(3), 201-205 (2006).
52. Jung KY, Fletcher S. Fine-tuning the chemo-and regioselective alkylation of 1,4-benzodiazepines: further applications of the Mitsunobu reaction. Med. Chem. Commun. 3, 1160-1163 (2012).
53. Ripka WC, De Lucca GV, Bach Ii AC, Pottorf RS, Blaney JM. Protein b-turn mimetics I. Design, synthesis, and evaluation in model cyclic peptides. Tetrahedron 49(17), 3593-3608 (1993).
54. Volonterio A, Moisan L, Rebek J Jr. Synthesis of pyridazine-based scaffolds as a-helix mimetics. Org. Lett. 9(19), 3733-3736 (2007).
55. Santos JS, Voisin-Chiret AS, Burzicki G et al. Structural characterizations of oligopyridyl foldamers, a-helix mimetics. J. Chem. Inf. Model 52(2), 429-439 (2012).
56. Biros SM, Moisan L, Mann E et al. Heterocyclic a-helix mimetics for targeting protein-protein interactions. Bioorg. Med. Chem. Lett. 17(16), 4641-4645 (2007). (Pubitemid 47064505)
57. Cummings CG, Ross NT, Katt WP, Hamilton AD. Synthesis and biological evaluation of a 5-6-5 imidazole-phenyl-thiazole based a-helix mimetic. Org. Lett. 11(1), 25-28 (2009).
58. Cummings CG, Hamilton AD. Expedient route to functionalized and water soluble 5-6-5 imidazole-phenyl-thiazole based a-helix mimetics Tetrahedron 69, 1663-1668 (2013).
59. Maity P, Konig B. Synthesis and structure of 1,4-dipiperazino benzenes: chiral terphenyl-type peptide helix mimetics. Org. Lett. 10(7), 1473-1476 (2008).
60. Tosovska P, Arora PS. Oligooxopiperazines as nonpeptidic a-helix mimetics. Org. Lett. 12(7), 1588-1591 (2010).
61. Ehlers I, Maity P, Aube J, Konig B. Modular Synthesis of triazole-containing triaryl a-helix mimetics. Eur. J. Org. Chem. 2474-2490 (2011).
62. Antuch W, Menon S, Chen QZ et al. Design and modular parallel synthesis of a MCR derived a-helix mimetic protein-protein interaction inhibitor scaffold. Bioorg. Med. Chem. Lett. 16(6), 1740-1743 (2006). (Pubitemid 43197557)
63. Lee JH, Zhang Q, Jo S et al. Novel pyrrolopyrimidine-based a-helix mimetics. cell-permeable inhibitors of protein-protein interactions. J. Am. Chem. Soc. 133(4), 676-679 (2011).
64. Rodriguez JM, Hamilton AD. Intramolecular hydrogen bonding allows simple enaminones to structurally mimic the i, i + 4, and i + 7 residues of an a-helix. Tetrahedron Lett. 47, 7443-7446 (2006). (Pubitemid 44344795)
65. Adler MJ, Hamilton AD. Oligophenylenaminones as scaffolds for a-helix mimicry. J. Org Chem. 76(17), 7040-7047 (2011).
66. Rodriguez JM, Hamilton AD. Benzoylurea oligomers: synthetic foldamers that mimic extended a helices. Angew. Chem. Int. Ed. Engl. 46(45), 8614-8617 (2007). (Pubitemid 350189076)
67. Rodriguez JM, Ross NT, Katt WP, Dhar D, Lee GI, Hamilton AD. Structure and function of benzoylurea-derived a-helix mimetics targeting the Bcl-x(L)/Bak binding interface. ChemMedChem 4(4), 649-656 (2009).
68. Williams AB, Hanson RN. Synthesis of substituted biphenyl amino esters as a helix mimetics. Tetrahedron 68, 5406-5414 (2012).
69. Becerril J, Hamilton AD. Helix mimetics as inhibitors of the interaction of the estrogen receptor with coactivator peptides. Angew. Chem. Int. Ed. 46, 4471-4473 (2007). (Pubitemid 46954597)
70. Jacoby E. Biphenyls as potential mimetics of protein a-helix. Bioorg. Med. Chem. Lett. 12(6), 891-893 (2002). (Pubitemid 34214968)
71. Gomes CP, Metz A, Bats JW, Gohlke H, Gobel MW. Modular solid-phase synthesis of teroxazoles as a class of a-helix mimetics. Eur. J. Org. Chem. 17, 3270-3277 (2012).
72. Rodriguez JM, Nevola L, Ross NT, Lee GI, Hamilton AD. Synthetic inhibitors of extended helix-protein interactions based on a biphenyl 4,4́-dicarboxamide scaffold. Chembiochem. 10(5), 829-833 (2009).
73. Restorp P, Rebek J Jr. Synthesis of a-helix mimetics with four side-chains. Bioorg. Med. Chem. Lett. 18(22), 5909-5911 (2008).
74. Cornette JL, Cease KB, Margalit H, Spouge JL, Berzofsky JA, Delisi C. Hydrophobicity scales and computational techniques for detecting amphipathic structures in proteins. J. Mol. Biol. 195(3), 659-685 (1987).
75. Marimganti S, Cheemala MN, Ahn JM. Novel amphiphilic a-helix mimetics based on a bis-benzamide scaffold. Org. Lett. 11(19), 4418-4421 (2009).
76. Thompson S, Vallinayagam R, Adler MJ, Scott RTW, Hamilton AD. Double-sided a-helix mimetics. Tetrahedron 68, 4501-4505 (2012).
77. Thompson S, Hamilton AD. Amphiphilic a-helix mimetics based on a benzoylurea scaffold. Org. Biomol. Chem. 10(30), 5780-5782 (2012).
78. Jung KY, Vanommeslaeghe K, Lanning ME et al. Amphipathic a-helix mimetics based on a 1,2-diphenylacetylene scaffold. Org. Lett. 15(13), 3234-3237 (2013).